

# DON'T MISS A **DIAGNOSIS.**

BIOFIRE® rapid syndromic PCR testing for infectious diseases



BIOFIRE®  
RESPIRATORY 2.1  
PANEL



BIOFIRE®  
BLOOD CULTURE  
IDENTIFICATION 2 PANEL



BIOFIRE® FILMARRAY®  
GASTROINTESTINAL  
PANEL



BIOFIRE® FILMARRAY®  
MENINGITIS/  
ENCEPHALITIS PANEL



BIOFIRE® FILMARRAY®  
PNEUMONIA PANEL



BIOFIRE®  
JOINT INFECTION  
PANEL



BIOFIRE®  
SYNDROMIC TRENDS



BIOFIRE®  
FIREWORKS™






# BIOFIRE<sup>®</sup> Syndromic Testing

Don't miss the right test  
the first time.

<b>TRADITIONAL VS. SYNDROMIC TESTING</b>	<b>2</b>
<b>BIOFIRE<sup>®</sup> FILMARRAY<sup>®</sup> TORCH</b>	<b>5</b>
<b>BIOFIRE<sup>®</sup> SYNDROMIC TESTING PANELS</b>	<b>8</b>
<b>RESPIRATORY</b>	<b>8</b>
<b>PNEUMONIA</b>	<b>10</b>
<b>GASTROINTESTINAL</b>	<b>11</b>
<b>MENINGITIS/ENCEPHALITIS</b>	<b>12</b>
<b>BLOODSTREAM INFECTION</b>	<b>13</b>
<b>JOINT INFECTION</b>	<b>14</b>
<b>DATA/IT SOLUTIONS</b>	<b>15</b>
<b>CUSTOMER SUPPORT</b>	<b>16</b>

**The BIOFIRE® line of products  
from bioMérieux is evolving  
infectious disease diagnostics.**

**The BIOFIRE syndromic approach  
empowers clinicians and lab  
personnel to choose the right test  
the first time.**




The BIOFIRE® syndromic approach is a symptom-driven broad grouping of probable pathogens into one rapid test. Using multiplex PCR technology, a BIOFIRE syndromic test targets a comprehensive menu of microorganisms that may present with similar signs and symptoms. The syndromic approach **maximizes the chance of getting the right answer in a clinically relevant time frame.**

Targeted infectious disease diagnostics limit testing to only a few pathogens associated with a clinical syndrome. By using a molecular syndromic approach and a broad test menu, syndromic testing from BIOFIRE can better detect and identify the target with just one easy diagnostic test.

As the industry leader, bioMérieux sets the standard for syndromic infectious disease diagnostics. While the BIOFIRE technology is highly sophisticated, simplicity is a trademark characteristic of the BIOFIRE System. BIOFIRE offers 6 comprehensive panels that are US FDA-cleared and/or CE-marked, for the most pathogen and antimicrobial resistance gene detection. Our innovative, easy-to-use solutions help health care providers better detect and identify infectious targets, enabling quicker, more effective patient care.


## Traditional Testing

Traditional methods of pathogen identification can be time consuming and lack sensitivity.<sup>1</sup>



## Syndromic Testing

Syndromic testing provides a streamlined workflow and fast, comprehensive results.




1. Cybulski RJ, et al. Clin Infect Dis. 2018;67(11):1688-96.



# The BIOFIRE® FILMARRAY® TORCH

The most advanced syndromic testing



Scalable configuration with a modular design from 1 to 12 modules



High throughput for running up to 351 tests per day



Optimized footprint with just 18 in. (46 cm.) of bench space needed

2. Calculations based on running the BIOFIRE® Respiratory 2.1 plus Panel over a 24-hour day.

# Easier Testing, Faster Results



## 2 minutes of hands-on time

Sample preparation and test loading are quick and easy, taking just two minutes of hands-on time to complete.



## Results in about an hour

The BIOFIRE TORCH's automated syndromic molecular test can be completed in about an hour.



## Bidirectional connection to LIS

The BIOFIRE TORCH can be interfaced with the Laboratory Information System (LIS) in either unidirectional or bidirectional HL7 configurations—saving time and reducing the likelihood of error without sacrificing data security. The BIOFIRE TORCH is capable of interfacing with most major LIS.




## All-in-one technology

The user-friendly, multiplex, nested PCR system incorporates sample preparation, amplification, detection, and analysis in one pouch.



## Any tech, any shift

With no precise pipetting required, the BIOFIRE TORCH can be easily used by any tech on any shift at any size institution.\*



\*Can be run by any technician with proper laboratory training





*“In conclusion, the BIOFIRE® FILMARRAY® Gastrointestinal Panel is a broad, multiplex gastrointestinal panel with a rapid turnaround time, resulting in a significant reduction of unnecessary isolation days, antibiotic therapy and prevention of additional diagnostic procedures in patients with clinical suspicion of infectious gastroenteritis.”<sup>3</sup>*

## **Julian Machiels, MD**

Consultant Microbiologist

3. Machiels J., et al. Impact of the BioFire FilmArray gastrointestinal panel on patient care and infection control. PLoS One. 2020;15(2):e0228596. Published 2020 Feb 6. doi:10.1371/journal.pone.0228596.

# Fast Answers with BIOFIRE® Syndromic Panels

## Comprehensive panels offer better diagnostics

Comprehensive panels remove the guesswork. Each BIOFIRE Panel targets an infectious disease syndrome by combining a broad grouping of probable pathogenic causes into a single test.

The FDA cleared and/or CE-marked BIOFIRE Panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes.

**170+**  
**TARGETS**  
**~1hr**



**BIOFIRE® RESPIRATORY 2.1 PANEL**



**BIOFIRE® FILMARRAY® PNEUMONIA PANEL**



**BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL**



**BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL**



**BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL**



**BIOFIRE® JOINT INFECTION PANEL**

Product availability varies by country. Consult your bioMérieux representative.



# BIOFIRE® RESPIRATORY 2.1 (RP2.1) PANEL

Sample Type: 0.3 mL of nasopharyngeal swab in transport media or saline

## 1 Test. 22 Targets. ~45 Minutes.

The BIOFIRE RP2.1 Panel identifies the most common viral and bacterial pathogens—including SARS-CoV-2—that cause respiratory tract infections, which can present with nearly indistinguishable symptoms. An unprecedented run time of about 45 minutes enables higher efficiency and throughput on the BIOFIRE® FILMARRAY® 2.0 and the BIOFIRE® FILMARRAY® TORCH Systems. Rapid and accurate respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.

## Panel Menu

### VIRUSES

Adenovirus  
Coronavirus 229E  
Coronavirus HKU1  
Coronavirus NL63  
Coronavirus OC43  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
Human metapneumovirus  
Human rhinovirus/enterovirus

Influenza A virus  
Influenza A virus A/H1  
Influenza A virus A/H3  
Influenza A virus A/H1-2009  
Influenza B virus  
Parainfluenza virus 1  
Parainfluenza virus 2  
Parainfluenza virus 3  
Parainfluenza virus 4  
Respiratory syncytial virus

### BACTERIA

*Bordetella parapertussis*  
*Bordetella pertussis*  
*Chlamydia pneumoniae*  
*Mycoplasma pneumoniae*

**Overall Performance:** 97.1% sensitivity, 99.3% specificity<sup>4</sup>

**SARS-CoV-2 Performance:** 98.4% PPA, 98.9% NPA<sup>5</sup>

FDA cleared

4. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel, data on file, BioFire Diagnostics.

5. Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, data on file, BioFire Diagnostics.



# BIOFIRE® FILMARRAY® PNEUMONIA (PN) PANEL

Sample Type: Sputum-like (including ETA) and BAL-like (including BAL and mini BAL)

## 1 Test. 33 Targets. ~1 Hour.

Rapid identification of probable causative pathogens and antimicrobial resistance genes can help healthcare providers quickly determine how best to treat a lower respiratory tract infection. The BIOFIRE PN Panel tests for 26 of the most common bacterial and viral pathogens associated with pneumonia, along with 7 antimicrobial resistance genes.

## Panel Menu

### BACTERIA (SEMI-QUANTITATIVE)

*Acinetobacter calcoaceticus-  
baumannii* complex  
*Enterobacter cloacae* complex  
*Escherichia coli*  
*Haemophilus influenzae*  
*Klebsiella aerogenes*  
*Klebsiella oxytoca*  
*Klebsiella pneumoniae* group  
*Moraxella catarrhalis*  
*Proteus* spp.  
*Pseudomonas aeruginosa*  
*Serratia marcescens*  
*Staphylococcus aureus*  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*  
*Streptococcus pyogenes*

### ATYPICAL BACTERIA (QUALITATIVE)

*Chlamydia pneumoniae*  
*Legionella pneumophila*  
*Mycoplasma pneumoniae*

### VIRUSES

Adenovirus  
Coronavirus  
Human metapneumovirus  
Human rhinovirus/enterovirus  
Influenza A virus  
Influenza B virus  
Parainfluenza virus  
Respiratory syncytial virus

### ANTIMICROBIAL RESISTANCE GENES

#### Carbapenemases

IMP  
KPC  
NDM  
OXA-48-like  
VIM

#### ESBL CTX-M

#### Methicillin Resistance *mecA/C* and MREJ (MRSA)

**Performance:** BAL-like (including BAL and mini-BAL): 96.2% sensitivity, 98.3% specificity;  
Sputum-like (including ETA): 96.3% sensitivity, 97.2% specificity<sup>6</sup>

FDA cleared | CE<sub>2797</sub>

<sup>6</sup> Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Pneumonia Panel, data on file, BioFire Diagnostics.



# BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL

Sample Type: 0.2 mL stool collected in Cary Blair transport medium

## 1 Test. 22 Targets. ~1 Hour.

The BIOFIRE GI Panel tests stool in Cary Blair for the bacteria, viruses, and parasites most commonly associated with gastroenteritis. Quickly identifying the probable pathogen can ensure appropriate targeted treatment and patient management and help decrease infectious gastroenteritis, which can lead to prolonged or severe illness.

## Panel Menu

### BACTERIA

*Campylobacter (C. jejuni/C. coli/C. upsaliensis)*  
*Clostridioides (Clostridium) difficile (toxin A/B)*  
*Plesiomonas shigelloides*  
*Salmonella*  
*Vibrio (V. parahaemolyticus/V. vulnificus/V. cholerae)*  
*Vibrio cholerae*  
*Yersinia enterocolitica*  
Diarrheagenic *Escherichia coli/Shigella*  
Enterohaggative *E. coli* (EAEC)  
Enteropathogenic *E. coli* (EPEC)  
Enterotoxigenic *E. coli* (ETEC) *lt/st*  
Shiga-like toxin-producing *E. coli* (STEC) *stx1/stx2*  
*E. coli* O157  
*Shigella/Enteroinvasive E. coli* (EIEC)

### VIRUSES

Adenovirus F40/41  
Astrovirus  
Norovirus GI/GII  
Rotavirus A  
Sapovirus (I, II, IV, and V)

### PARASITES

*Cryptosporidium*  
*Cyclospora cayetanensis*  
*Entamoeba histolytica*  
*Giardia lamblia*

**Performance:** 98.5% sensitivity, 99.2% specificity<sup>7</sup>

FDA cleared | CE<sub>2797</sub>

<sup>7</sup> Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Gastrointestinal Panel, data on file, BioFire Diagnostics.



# BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS (ME) PANEL

Sample Type: 0.2 mL of cerebrospinal fluid (CSF)

## 1 Test. 14 Targets. ~1 Hour.

Every minute counts and time to diagnosis is critical when it comes to meningitis and encephalitis. The right treatment depends on quick identification of the pathogen as bacterial, viral, or yeast. The BIOFIRE ME Panel utilizes a syndromic approach—simultaneously testing for a comprehensive set of 14 of the most common pathogens associated with central nervous system (CNS) infections—to deliver actionable results in about an hour, allowing clinicians to make timely and optimal treatment decisions.

## Panel Menu

### BACTERIA

*Escherichia coli* K1  
*Haemophilus influenzae*  
*Listeria monocytogenes*  
*Neisseria meningitidis*  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*

### VIRUSES

Cytomegalovirus (CMV)  
Enterovirus (EV)  
Herpes simplex virus 1 (HSV-1)  
Herpes simplex virus 2 (HSV-2)  
Human herpesvirus 6 (HHV-6)  
Human parechovirus (HPeV)  
Varicella zoster virus (VZV)

### YEAST

*Cryptococcus (C. neoformans/C. gattii)*

**Performance:** 94.2% sensitivity, 99.8% specificity<sup>8</sup>

FDA cleared | CE<sub>2797</sub>

<sup>8</sup> Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel, data on file, BioFire Diagnostics.



# BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL

Sample Type: 0.2 mL positive blood culture media

## 1 Test. 43 Targets. ~1 Hour.

The BIOFIRE BCID2 Panel tests a single positive blood culture sample to simultaneously provide results for multiple organisms and organism groups that cause bloodstream infections, as well as genetic markers associated with antimicrobial resistance. Rapid identification of the organism(s) in the blood culture, along with information about antimicrobial resistance gene presence for select microorganisms, may aid in making appropriate treatment decisions.<sup>9</sup>

## Panel Menu

### GRAM-NEGATIVE BACTERIA

*Acinetobacter calcoaceticus-baumannii* complex  
*Bacteroides fragilis*  
Enterobacterales  
*Enterobacter cloacae* complex  
*Escherichia coli*  
*Klebsiella aerogenes*  
*Klebsiella oxytoca*  
*Klebsiella pneumoniae* group  
*Proteus* spp.  
*Salmonella* spp.  
*Serratia marcescens*  
*Haemophilus influenzae*  
*Neisseria meningitidis*  
*Pseudomonas aeruginosa*  
*Stenotrophomonas maltophilia*

### GRAM-POSITIVE BACTERIA

*Enterococcus faecalis*  
*Enterococcus faecium*  
*Listeria monocytogenes*  
*Staphylococcus* spp.  
*Staphylococcus aureus*  
*Staphylococcus epidermidis*  
*Staphylococcus lugdunensis*  
*Streptococcus* spp.  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*  
*Streptococcus pyogenes*

### YEAST

*Candida albicans*  
*Candida auris*  
*Candida glabrata*  
*Candida krusei*  
*Candida parapsilosis*  
*Candida tropicalis*  
*Cryptococcus (C. neoformans/C. gattii)*

### ANTIMICROBIAL RESISTANCE GENES

#### Carbapenemases

IMP  
KPC  
OXA-48-like  
NDM  
VIM

#### Colistin Resistance

*mcr-1*

#### ESBL

CTX-M

#### Methicillin Resistance

*mecA/C*  
*mecA/C* and MREJ (MRSA)

#### Vancomycin Resistance

*vanA/B*

**Performance:** 99.0% sensitivity, 99.8% specificity<sup>10</sup>

FDA cleared |  2797

9. Sparks R, et al. Pathology. 2021. 53(7):889-895

10. Overall performance is the aggregate of the prospective, archived, and seeded data from the clinical studies. Data on file, BioFire Diagnostics.



# BIOFIRE® JOINT INFECTION (JI) PANEL

Sample Type: 0.2 mL of synovial fluid

## 1 Test. 39 Targets. ~1 Hour.

The BIOFIRE JI Panel tests for common causes of prosthetic joint infections and septic arthritis. The BIOFIRE JI Panel includes assays for 39 targets, including gram-positive bacteria, gram-negative bacteria, yeast, and antibiotic resistance genes. Through rapid pathogen identification, the BIOFIRE JI Panel may aid in pathogen guided patient management.

## Panel Menu

### GRAM-POSITIVE BACTERIA

*Anaerococcus prevotii/vaginalis*  
*Clostridium perfringens*  
*Cutibacterium avidum/granulosum*  
*Enterococcus faecalis*  
*Enterococcus faecium*  
*Fingoldia magna*  
*Parvimonas micra*  
*Peptoniphilus*  
*Peptostreptococcus anaerobius*  
*Staphylococcus aureus*  
*Staphylococcus lugdunensis*  
*Streptococcus* spp.  
*Streptococcus agalactiae*  
*Streptococcus pneumoniae*  
*Streptococcus pyogenes*

### GRAM-NEGATIVE BACTERIA

*Bacteroides fragilis*  
*Citrobacter*  
*Enterobacter cloacae* complex  
*Escherichia coli*  
*Haemophilus influenzae*  
*Kingella kingae*  
*Klebsiella aerogenes*  
*Klebsiella pneumoniae* group  
*Morganella morganii*  
*Neisseria gonorrhoeae*  
*Proteus* spp.  
*Pseudomonas aeruginosa*  
*Salmonella* spp.  
*Serratia marcescens*

### YEAST

*Candida* spp.  
*Candida albicans*

### ANTIMICROBIAL RESISTANCE GENES

#### Carbapenemases

IMP  
KPC  
NDM  
OXA-48-like  
VIM

#### ESBL

CTX-M

#### Methicillin Resistance

*mecA/C* and MREJ (MRSA)

#### Vancomycin Resistance

*vanA/B*

**Performance:** 91.7% sensitivity, 99.8% specificity<sup>11</sup>

FDA cleared | CE<sub>2797</sub>

11. Overall performance based on prospective clinical study for the BIOFIRE® Joint Infection Panel, data on file, BioFire Diagnostics.



# Data-driven Decision Making

Take your BIOFIRE® Systems even further with BIOMÉRIEUX VISION SUITE.

BIOMÉRIEUX VISION SUITE turns laboratory and hospital data into insightful, actionable information to support diagnostic and clinical decisions at all stages to better support antimicrobial stewardship.

By providing a comprehensive suite of software solutions that collect, analyze, and merge various sources of data, BIOMÉRIEUX VISION SUITE empowers you to make the right decisions at the right time.



## BIOFIRE® SYNDROMIC TRENDS (TREND)

Turn BIOFIRE® System results into smart pathogen trending.

Creating a global epidemiology network that displays BIOFIRE Panel test results from participating laboratories and hospitals around the world. BIOFIRE TREND allows users to explore epidemiology insights and better understand site-specific and regional pathogen trends and seasonality.



## BIOFIRE® FIREWORKS™

Optimizing laboratory services using data-driven solutions.

Providing users total insights and analytics into BIOFIRE® System performance, utilization, pathogen surveillance, and laboratory workflow management. FIREWORKS can save your lab time, help lessen workloads, and create more efficient workflows.



# Peace of Mind All the Time

## First in diagnostics. First in customer care.

bioMérieux has a skilled team dedicated to client success. Our customer support team provides global product support, solution training courses, LIS connectivity assistance, and instrument or chemistry related troubleshooting. We are committed to the speedy resolution of all technical issues, maximized when using VILINK® for a remote support and troubleshooting through a secure connection. Moreover VILINK® enables automatic software, firmware and security updates—including FIREWORKS installation and updates.



### International Support

For international BIOFIRE technical assistance and support, please contact your local bioMérieux representative or distributor.




### Help at Your Fingertips

With a complete suite of resources, our customers have access to everything they need for set-up, verification, and integration of BIOFIRE® FILMARRAY® Systems.

Our website provides documents to assist with verification, EC Declarations of Conformity, and continuing education for all customers.

Visit [biofire.com](https://www.biofire.com) to find Advisory Notices, Information Sheets, Product Support Documents, and other resources.





The purchase of this product includes a limited, non-transferable license under specific claims of one or more US patents listed on the BioFire Diagnostics website (<http://www.biofire.com/legal-notices/>) owned by BioFire and/or the Research Foundation of The University of Utah. The blue logo, BIOFIRE and FILMARRAY logos, and BIOMÉRIEUX, BIOFIRE, and FILMARRAY are used, pending, and/or registered trademarks belonging to bioMérieux or BioFire or one of their subsidiaries or companies. Document and/or picture not legally binding. Modifications can be made without prior notice. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without the express written permission of bioMérieux / BioFire Diagnostics.

## Contact Us

bioMérieux S.A.  
69280 Marcy l'Etoile  
France  
Tel: +33 (0) 4 78 87 20 00  
Fax: +33 (0) 4 78 87 20 90  
**biomerieux.com**

Product availability varies by country. Consult your bioMérieux representative.

9323703 007/GB/C BFR0001-4857-03